AbbVie pens Imbruvica supply pact to support pivotal Oncternal trial

AbbVie has helped Oncternal Therapeutics move a step closer to the start of a phase 3 trial by agreeing to supply the Bruton’s tyrosine kinase inhibitor ibrutinib for use in the study.